By vgreene, 13 October, 2020 <b>Study considerations:</b> randomized but open label; HCQ dose based on PK modeling; limited number of intubated pts; no children enrolled; no collection of virological or laboratory parameters
By vgreene, 13 October, 2020 28-day all-cause mortality higher w/ HCQ vs SOC only (RR 1.09, 95% CI 0.97 to 1.23), similarly across subgroups; HCQ group less likely to be discharged alive w/in 28 days vs SOC (rate ratio 0.9, 95% CI 0.83-0.98); among pts not mech vent baseline, HCQ gro
By vgreene, 13 October, 2020 Hospitalized pts (mean age 65.4y) w/ suspected or confirmed COVID-19 randomized to HCQ 800 mg q6h x2, then 400 mg q12h plus SOC for up to 10 days (n=1,561) vs SOC only (n=3,155); at randomization 17% invasive mech vent, 60% O<sub>2</sub> only
By vgreene, 13 October, 2020 Randomized, controlled, open-label, adaptive platform study; current analysis incl HCQ vs SOC only, results for other tx arms published or forthcoming
By vgreene, 13 October, 2020 Effect of Hydroxychloroquine in Hospitalized Patients With Covid 19 RECOVERY
By vgreene, 13 October, 2020 Secondary outcome of improvement odds at day 15 higher w/ RDV vs placebo (OR 1.5, 95% CI 1.2-1.9); lower mortality by day 15 w/ RDV (6.7% vs 11.9%) but no significant difference by day 29; no difference in ADR incidence
By vgreene, 13 October, 2020 <b>Monitor</b> at least monthly after tx start/change until remission (ie, 2mo w/o sx)<sup>ICSI</sup>
By vgreene, 13 October, 2020 If combining therapy w other tx APA recommends CBT interpersonal therapy SGA2
By vgreene, 13 October, 2020 1st line evidence based options acceptance commitment therapy behavioral therapy behavioral activation cognitive behavioral therapy cognitive therapy interpersonal therapy mindfulness based cognitive therapy problem solving therapy 1 3 short term psychody
By vgreene, 13 October, 2020 If choosing psychotherapy pt preference guides individual vs group model 3
